Johns Hopkins Medicine
Office of Corporate Communications
Media Contact: Trent Stockton 410-955-8665
March 25, 2004
JOHNS HOPKINS HOSTS NATIONAL CONFERENCE ON THE TREATMENT OF ALZHEIMER’S DISEASE AND DEMENTIA
Experts from across the United States will convene in Baltimore Friday and Saturday, Mar. 26-27, for a special conference, “On the Treatment of Alzheimer’s Disease and Other Dementias,” hosted by Johns Hopkins. The conference, held in the Thomas B. Turner Building at The Johns Hopkins University School of Medicine, will focus on drug development for the treatment of Alzheimer’s and dementia.
According to the National Institute on Aging, up to 4 million Americans suffer from Alzheimer’s disease. This number is likely to grow to over 12 million in the next few decades. As the population continues to age, the need for effective drug treatments and medical care for Alzheimer’s patients grows exponentially. Currently, there is no cure for the disease.
Also planned is a staged reading of The Augusta File, a play based on a conversation between Alois Alzheimer and Augusta Deter, the 51-year-old woman whom Alzheimer first described as suffering from the disease in 1906, as recorded in his clinical notes on the case. Written by Konrad and Ulrike Maurer, the play will be read at 6 p.m, Friday, March 26.
“By bringing together a spectrum of health care professionals working on dementia – physicians, pharmacologists, psychiatrists, neurologists, historians, anthropologists and others – new perspectives on the disease will emerge, along with renewed hope for a cure,” says Constantine Lyketsos, M.D., professor of psychiatry and behavioral sciences at Johns Hopkins and one of the conference organizers.
The conference is sponsored by Johns Hopkins Medicine, the Johns Hopkins Alzheimer’s Disease Research Center, the Copper Ridge Institute, the greater Maryland chapter of the Alzheimer’s Association, the University Memory and Aging Center of the University Hospitals of Cleveland/Case Western Reserve University, and the University of Pennsylvania’s Alzheimer’s Disease Center. The American Geriatrics Society is a co-sponsor.
- David Healy, M.D., reader in psychological medicine, University of North Wales, England. History of drug development for Alzheimer’s.
- Margaret Lock, Ph.D., professor of anthropology, McGill University, Montreal, Quebec, Canada. Social and cultural context of drug treatment.
- Leon Thal, M.D., professor and chairman of neurosciences, School of Medicine, University of California San Diego. The Alzheimer’s Disease Cooperative Study.
- Peter Whitehouse, MD, director of integrative studies, Case Western Reserve University. The emergence of “mild cognitive impairment.”
- Marilyn Albert, Ph.D., professor of neurology, psychiatry and behavioral sciences, Johns Hopkins. Brain imaging and Alzheimer’s Disease.
- Donald Price, M.D., professor of pathology, neuropathology, and neuroscience, Johns Hopkins. Development of new drugs for Alzheimer’s.
- Charles E. Rosenberg, Ph.D., professor and chair of the history of science, Harvard University. Science, politics, and defining disease.
For the complete program, visit: http://www.hopkinscme.org
Other related Web sites:
- -JHMI- -